benzylpenicilloyl g has been researched along with murabutide in 1 studies
| Studies (benzylpenicilloyl g) | Trials (benzylpenicilloyl g) | Recent Studies (post-2010) (benzylpenicilloyl g) | Studies (murabutide) | Trials (murabutide) | Recent Studies (post-2010) (murabutide) |
|---|---|---|---|---|---|
| 45 | 4 | 0 | 78 | 8 | 11 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auci, DL; Carucci, JA; Chice, SM; Dukor, P; Durkin, HG; Smith, MC | 1 |
1 other study(ies) available for benzylpenicilloyl g and murabutide
| Article | Year |
|---|---|
Control of IgE responses. 4. Isotype-specific suppression of peak BPO-specific IgE antibody-forming cell responses and of BPO-specific IgE in serum by muramyldipeptide or murabutide after administration to mice by gavage.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Administration, Oral; Animals; Antibody-Producing Cells; Benzeneacetamides; Enzyme-Linked Immunosorbent Assay; Hemocyanins; Immunoglobulin E; Immunoglobulin Isotypes; Immunoglobulins; Immunosuppression Therapy; Injections, Subcutaneous; Lymphoid Tissue; Male; Mice; Mice, Inbred BALB C; Penicillin G | 1993 |